top of page

iPharmaCenter

News | Blogs | Healthcare | Consulting

Contact: info@ipharmacenter.com

Home
Pharma
Healthcare News
Healthcare Policies
Disease News
Conferences
Others
- COVID-19
- Contact

Hello USA and Canada

Find the drug and healthcare news of the USA and Canada.

AstraZeneca's ADC Enhertu is now approved in US for HR-positive, HER2-low or ultra low breast cancer | iPharmaCenter

BeiGene's PD-L1 inhibitor Tevimbra approved in the US for advanced gastric or gastroesophageal junction (G/GEJ) cancers | iPharmaCenter

FDA Devices Approval | 2024 | Abbott News | iPharmaCenter

FDA Devices Approval | 2024 | Abbott News | iPharmaCenter

FDA Diagnostics Approvals | 2024 | FDA Approvals | iPharmaCenter

FDA Diagnostics Approvals | 2024 | FDA Approvals | iPharmaCenter

Centers for Disease Control and Prevention | CDC | iPharmaCenter | 2024

Centers for Disease Control and Prevention | CDC | iPharmaCenter | 2024

Express-Scripts | Pharmacy Benefit Manager | News | Updates | 2024 | US Healthcare | iPharmaCenter

Express-Scripts | Pharmacy Benefit Manager | News | Updates | 2024 | US Healthcare | iPharmaCenter

Eisai's Leqembi received FDA approval for Alzheimer's | CMS coverage of Leqembi | ipharmacenter

Eisai's Leqembi received FDA approval for Alzheimer's | CMS coverage of Leqembi | ipharmacenter

COVID19 drug updates | FDA EMA approved COVID19 drugs

COVID19 drug updates | FDA EMA approved COVID19 drugs

Genzyme's Xenpozyme approved for Acid Sphingomyelinase Deficiency | iPharmaCenter

Genzyme's Xenpozyme approved for Acid Sphingomyelinase Deficiency | iPharmaCenter

Lilly's and Incyte's Olumiant approved for adults with severe alopecia areata

Lilly's and Incyte's Olumiant approved for adults with severe alopecia areata

Myasthenia Gravis News | FDA and EMA approvals |

Myasthenia Gravis News | FDA and EMA approvals |

American College of Rheumatology (ACR) Convergence all-virtual annual meeting Updates

American College of Rheumatology (ACR) Convergence all-virtual annual meeting Updates

FDA approved Novartis Scembli for chronic myeloid leukemia

FDA approved Novartis Scembli for chronic myeloid leukemia

Biogen's Aduhelm received FDA approval for Alzheimer's disease; ICER criticized approval

Biogen's Aduhelm received FDA approval for Alzheimer's disease; ICER criticized approval

GSK’s Jemperli received approval in Europe and the US for endometrial cancer

GSK’s Jemperli received approval in Europe and the US for endometrial cancer

BMS’ and bluebird bio’s Abecma approved by US FDA; first CAR T cell therapy for multiple myeloma

Novartis’ blockbuster Entresto received the US FDA approval for a broader target population

US FDA approved BMS gene therapy Breyanzi

US FDA approved BMS gene therapy Breyanzi

Merck and Bayer announced the US FDA approval for Verquvo

Novartis and BeiGene collaboration strengthens the Swiss drugmaker's oncology portfolio

Novartis and BeiGene collaboration strengthens the Swiss drugmaker's oncology portfolio

Biogen initiated Phase 4 trial to determine the efficacy of Spinraza in Zolgensma treated patients

REGENERON'S INMAZEB FIRST PRODUCT TO RECEIVE FDA APPROVAL FOR TREATING EBOLA VIRUS

REGENERON'S INMAZEB FIRST PRODUCT TO RECEIVE FDA APPROVAL FOR TREATING EBOLA VIRUS

FDA approved GSK’s Nucala for Hypereosinophilic Syndrome

FDA approved GSK’s Nucala for Hypereosinophilic Syndrome

J&J has initiated the Phase 3 clinical trial of the COVID-19 vaccine

J&J has initiated the Phase 3 clinical trial of the COVID-19 vaccine

Pfizer received the approval of Xalkori for ALK-positive anaplastic large cell lymphoma

Pfizer received the approval of Xalkori for ALK-positive anaplastic large cell lymphoma

FDA approved Trelegy Ellipta for asthma, GSK’s triple therapy is now available for asthma and COPD

FDA approved Trelegy Ellipta for asthma, GSK’s triple therapy is now available for asthma and COPD

Oxford vaccine trials were paused because of safety concerns; AZ said it’s ‘routine’

Oxford vaccine trials were paused because of safety concerns; AZ said it’s ‘routine’

FDA extended emergency use authorization of Veklury to all hospitalized patients

FDA extended emergency use authorization of Veklury to all hospitalized patients

FDA has provided emergency use authorization for Abbott’s easy-to-use COVID-19 antigen test

FDA has provided emergency use authorization for Abbott’s easy-to-use COVID-19 antigen test

FDA issued Emergency Use Authorization of Convalescent Plasma for COVID-19 treatment

FDA issued Emergency Use Authorization of Convalescent Plasma for COVID-19 treatment

Johnson and Johnson acquired Momenta Pharmaceuticals, aims to strength immunology profile

Amgen’s Kyprolis and Janssen’s Darzalex combination approved by the US FDA for multiple myeloma

Amgen’s Kyprolis and Janssen’s Darzalex combination approved by the US FDA for multiple myeloma

Novartis Kesimpta approved for relapsing multiple sclerosis in the US

Novartis Kesimpta approved for relapsing multiple sclerosis in the US

FDA says no to Gilead’s most anticipated product filgotinib

FDA says no to Gilead’s most anticipated product filgotinib

Genentech’s Enspryng approved for Neuromyelitis Optica Spectrum Disorder in the US

Genentech’s Enspryng approved for Neuromyelitis Optica Spectrum Disorder in the US

Gilead submitted NDA for Veklury to treat COVID-19 in the US

FDA approved Genentech’s Evrysdi for Spinal Muscular Atrophy

NOVARTIS COSENTYX APPROVED IN EUROPE FOR PAEDIATRIC PSORIASIS

GSK’s first anti-BCMA therapy Blenrep was approved in the US

Gilead’s CAR-T cell therapy approved for Relapsed or Refractory Mantle Cell Lymphoma

The US FDA approved Janssen’s psoriasis blockbuster for Psoriatic Arthritis

UNITED STATES HEALTHCARE SYSTEM

UNITED STATES HEALTHCARE SYSTEM

US FDA approved Rukobia (fostemsavir) for HIV patients who have limited treatment options

JANSSEN STOPPED PHASE 3 TRIAL OF ITS BLOCKBUSTER

US FDA approved Epizyme’s Tazverik for Relapsed/Refractory Follicular Lymphoma

Eli Lilly Lyumjev secures the US FDA approval for type-1 and type-2 diabetes

Novartis Ilaris to be the first FDA approved treatment for Adult-Onset Still’s Disease (AOSD)

FDA approved Novartis Cosentyx and Lilly’s Taltz for nr-axSpA in June

AMERICAN ACADEMY OF DERMATOLOGY CONFERENCE 2020

AMERICAN ACADEMY OF DERMATOLOGY CONFERENCE 2020

Viela Bio’s Uplizna received FDA approval for neuromyelitis optica spectrum disorder

For sponsored articles, link insertions, and advertisements, please write to info@ipharmacenter.com

Find the latest pharma and healthcare news on Telegram now. Simply scan the QR code.

Rephrase with Ginger (Cmd+⌥+E)

bottom of page